Pegfilgrastim-cbqv On-Body Injector Approved by FDA for Febrile Neutropenia Infection

News
Article

The on-body injector, pegfilgrastim-cbqv, has been approved by the FDA for patients who experience febrile neutropenia after chemotherapy.

The on-body injector, pegfilgrastim-cbqv, has been approved by the FDA for patients who experience febrile neutropenia after chemotherapy.

The on-body injector, pegfilgrastim-cbqv, has been approved by the FDA for patients who experience febrile neutropenia after chemotherapy.

The FDA has approved pegfilgrastim-cbqv (Udenyca Onbody) an on-body injector biosimilar given the day after chemotherapy to decrease the incidence of infection caused by febrile neutropenia, according to a press release from Coherus BioSciences.

The on-biody biosimiliar includes an indicator with a status light and auditory signal to determine correct dosing, as well as a strong and well-tolerated adhesive. Additionally, once the dose has been given, the needle will retract to reduce the risk of needlestick injury. This approval occurred from thorough pharmacokinetic, pharmacodynamic bioequivalence data, plus adhesive performance and tolerability data.

In the first quarter of 2024, the on-body injector is planned to be commercially available.

“The on-body injector for [pegfilgrastim] is the result of years of significant investment in research and development to bring forward a novel and proprietary device that provides patients with an automatic delivery option for their medication,” Denny Lanfear, chief executive office of Coherus, said in the press release. “[Patients with cancer] and their physicians will now be able to choose the [pegfilgrastim] administration presentation that best fits their individual needs: a prefilled syringe, our autoinjector, or this on-body injector.”

The use of this will help to reduce the risk of infection brought on by febrile neutropenia for patient with non-myeloid malignancies who have received myelosuppressive anti-cancer drugs with a significant incidence of febrile neutropenia. Additionally, this will help to increase survival for those who have myelosuppressive doses of radiation.

The press release noted the limitation for this on-body indication is for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. Patients who have serious allergic reactions to pegfilgrastim or products related to filgrastim should not be given this product.

“Our market studies showed a significant demand for a novel on-body pegfilgrastim delivery device tailored to specific patient needs. We expect that UDENYCA ONBODY’s five-minute injection time and innovative retractable needle mechanism will be well received by cancer patients, their caregivers, and doctors,” Paul Reider, Coherus’ chief commercial officer, said in the press release.

Reference

Coherus announces FDA approval of UDENYCA ONBODY™, a novel and proprietary state-of-the-art delivery system for pegfilgrastim-cbqv. News release. December 26, 2023. Coherus BioSciences. https://bit.ly/3tGt1bP

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content
Findings from a health disparities report may support new policies designed to narrow persistent racial and ethnic disparities in health outcomes.

Data Highlight Pervasive Racial/Ethnic Disparities in Health Care

May 3rd 2024
Article

Findings from a health disparities report may support new policies designed to narrow persistent racial and ethnic disparities in health outcomes.

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Lack of energy, difficulty with sleeping, and pain were some of the most common symptoms reported in older patients with cancer.

Elderly Cancer Populations Have Inconsistent Symptom Burden/Clusters

April 26th 2024
Article

Lack of energy, difficulty with sleeping, and pain were some of the most common symptoms reported in older patients with cancer.

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Addressing Rising Cancer Incidence and Burden in Younger Populations

March 11th 2024
Podcast

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Pediatric patients with acute lymphoblastic leukemia/lymphoma were less likely to have severe COVID-19 infection.

COVID-19 and Chemotherapy Association Holds in Pediatric Leukemia/Lymphoma

April 12th 2024
Article

Pediatric patients with acute lymphoblastic leukemia/lymphoma were less likely to have severe COVID-19 infection.

Patients with advanced solid tumors may be able to stay on treatment with saruparib longer compared with other approved PARP inhibitors, thereby improving efficacy.

Saruparib Shows Favorable Activity, Safety in Mutant Advanced Solid Tumors

April 8th 2024
Article

Patients with advanced solid tumors may be able to stay on treatment with saruparib longer compared with other approved PARP inhibitors, thereby improving efficacy.